{
    "medicine_id": "7b13c18f30b3193dcf3a67ea77d52bf5e71c1d88",
    "platform_id": "DB11793",
    "metadata": {
        "name": "Zejula 100 mg 1 Capsule",
        "composition": "100 mg 1 Niraparib",
        "clinical_particulars": {
            "therapeutic_indications": "Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum based chemotherapy",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Cardiovascular Effects Niraparib has the potential to cause effects on pulse rate and blood pressure in patients receiving the recommended dose which may be related to pharmacological inhibition of the dopamine transporter DAT norepinephrine transporter NET and serotonin transporter SERT In the NOVA study mean pulse rate and blood pressure increased over baseline in the niraparib arm relative to the placebo arm at all on study assessments Mean greatest increases from baseline in pulse rate on treatment were 24 1 and 15 8 beats min in the niraparib and placebo arms respectively Mean greatest increases from baseline in systolic blood pressure on treatment were 24 5 and 18 3 mmHg in the niraparib and placebo arms respectively Mean greatest increases from baseline in diastolic blood pressure on treatment were 16 5 and 11 6 mmHg in the niraparib and placebo arms respectively Cardiac Electrophysiology The potential for QTc prolongation with niraparib was evaluated in a randomized placebo controlled trial in cancer patients 367 patients on niraparib and 179 patients on placebo No large changes in the mean QTc interval 20 ms were detected in the trial following the treatment of niraparib 300 mg once daily",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Niraparib"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Niraparib"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Niraparib"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Niraparib"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}